TY - JOUR
T1 - PILOT TRIAL OF BRANCHED-CHAIN AMINOACIDS IN AMYOTROPHIC LATERAL SCLEROSIS
AU - Plaitakis, Adreas
AU - Mandeli, John
AU - Smith, Jeffrey
AU - Yahr, Melvin D.
N1 - Funding Information:
The work was supported by NIH Grants NS-16871 and NS-11631, The
PY - 1988/5/7
Y1 - 1988/5/7
N2 - 22 patients with amyotrophic lateral sclerosis were entered into a double-blind, randomised, placebo-controlled trial of treatment with branched-chain aminoacids. 11 received daily 12 g L-leucine, 8 g L-isoleucine, and 6·4 g L-valine, by mouth, and the remainder received placebo. During the one-year trial, patients in the placebo group showed a linear decline in functional status consistent with the natural history of the disease. Those treated with aminoacids showed significant benefit in terms of maintenance of extremity muscle strength and continued ability to walk.
AB - 22 patients with amyotrophic lateral sclerosis were entered into a double-blind, randomised, placebo-controlled trial of treatment with branched-chain aminoacids. 11 received daily 12 g L-leucine, 8 g L-isoleucine, and 6·4 g L-valine, by mouth, and the remainder received placebo. During the one-year trial, patients in the placebo group showed a linear decline in functional status consistent with the natural history of the disease. Those treated with aminoacids showed significant benefit in terms of maintenance of extremity muscle strength and continued ability to walk.
UR - http://www.scopus.com/inward/record.url?scp=0023913736&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(88)91841-7
DO - 10.1016/S0140-6736(88)91841-7
M3 - Article
C2 - 2896868
AN - SCOPUS:0023913736
SN - 0140-6736
VL - 331
SP - 1015
EP - 1018
JO - The Lancet
JF - The Lancet
IS - 8593
ER -